Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Fig. 2

Fulvestrant-resistant models show variable stability upon fulvestrant withdrawal. ac Fulvestrant dose-response curves (5 nM to 10 μM) and western blotting for ERα expression in fulvestrant-resistant (-FR) CAMA-1 (a), MCF7 (b), and HCC1428 (c) cells cultured either continuously with fulvestrant (+F, red solid lines) or after removal of fulvestrant (-F, red dotted lines) from the growth media for the indicated times (week 1-week 9). Parental (-P) cells cultured without fulvestrant were used as control (black solid lines). Graphs represent combined data (average ± SEM) from three biological replicates with at least three technical replicates each. Samples for western blotting were collected at each time-point and ERα protein expression was assessed. β-actin or β-tubulin was used as loading control. Representative data from three biological replicates is presented under each graph. Quantification of band intensities is presented in Additional file 4B-D. Stars indicate differences between fulvestrant-resistant cells grown with (red, solid lines) or without (red, dotted lines) fulvestrant. Stars are indicated at every other data point due to restricted space. Data for the ZR-75-1, T47D, and EFM-19 models are shown in Additional file 5

Back to article page
\